Elvina Almuradova/X
Sep 15, 2024, 10:22
Elvina Almuradova: DisACcontinuing anti-HER2 treatment in super responders could be considered
Elvina Almuradova, Medical Oncologist Ambassador at European School of Oncology, shared on X:
“Discontinuing anti-HER2 treatment in super responders could be considered, but trial results will be necessary to confirm this approach; meanwhile, hormone receptor status appears to be a major factor for disease progression.”
Source: Elvina Almuradova/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 13:29
Feb 21, 2025, 13:07
Feb 21, 2025, 13:06
Feb 21, 2025, 13:03
Feb 21, 2025, 13:00
Feb 21, 2025, 12:53
Feb 21, 2025, 12:41
Feb 21, 2025, 12:39